← Back to Conditions

Costeff syndrome

disorder
SNOMED 297232009CUI C0574084

Overview

Source: MedlinePlus.gov, National Library of Medicine. Not a substitute for medical advice.

Signs & Symptoms

Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.

3-methylglutaricaciduria
Always present (100%)HP:0003344
Optic atrophy
Always present (100%)HP:0000648
3-Methylglutaconic aciduria
Very frequent (80-99%)HP:0003535
Choreoathetoid movements
Very frequent (80-99%)HP:0001266
Impaired vision
Very frequent (80-99%)HP:0000505
Ataxia
Frequent (30-79%)HP:0001251
Difficulty articulating speech
Frequent (30-79%)HP:0001260
Involuntary, rapid, rhythmic eye movements
Frequent (30-79%)HP:0000639
Mental deficiency
Frequent (30-79%)HP:0001249
Spastic paraparesis
Frequent (30-79%)HP:0002313
Gait disturbance
Occasional (5-29%)HP:0001288
Choreiform movements
HP:0002072
Cognitive deficits
HP:0100543
Decreased visual acuity
HP:0007663
Extensor plantar responses
HP:0003487
Extrapyramidal dysfunction
HP:0002071
Increased reflexes
HP:0001347
Involuntary muscle stiffness, contraction, or spasm
HP:0001257

Quick Facts

SNOMED CT
297232009
UMLS CUI
C0574084
Fully Specified Name
3-Methylglutaconic aciduria type 3 (disorder)
Specialists
0
Diagnostic Biomarkers
0
HPO Phenotypes
18
Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.